CXCL9 Correlates with Experimental Neuromyelitis Optica Spectrum Disorder
Overview
This study identifies the role of AQP4-specific Tfh and Th17 cells in driving the pathology of neuromyelitis optica spectrum disorder (NMOSD). Notably, CXCL9 was found to be significantly upregulated and associated with astrocytic inflammation in the central nervous system.
Background
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition characterized by severe neuroinflammation and astrocyte injury, leading to significant neurological deficits. Understanding the pathogenic mechanisms, particularly the roles of specific T-cell subsets, is crucial for developing targeted therapies. This study explores the contributions of AQP4-specific Tfh and Th17 cells in NMOSD using a novel murine model.
Data Highlights
Finding
Details
Clinical Scores
Th17-transferred mice exhibited significantly more severe clinical scores compared to Tfh-transferred mice.
Histopathological Findings
Robust perivascular inflammation and focal demyelination were observed in recipient mice.
CXCL9 Expression
CXCL9 was identified as one of the most upregulated chemokines in the spinal cord.
Immune Cell Infiltration
Flow cytometry confirmed substantial infiltration of leukocytes and activated microglia/macrophages into the CNS.
Astrocytic Origin
CXCL9 expression was confirmed to be astrocyte-derived through confocal immunofluorescence.
Key Findings
AQP4-reactive Tfh and Th17 cells can induce key neuropathological features of NMOSD.
Th17 cells are associated with more severe clinical manifestations than Tfh cells.
Histopathological analysis revealed significant immune cell infiltration and demyelination.
CXCL9 was significantly upregulated in the spinal cord and linked to astrocytic inflammation.
Flow cytometric analysis demonstrated extensive leukocyte infiltration in the CNS.
Clinical Implications
The findings suggest that targeting CXCL9 and the associated T-cell subsets may provide new therapeutic avenues for NMOSD. Understanding the distinct roles of Tfh and Th17 cells could enhance the development of targeted immunotherapies.
Conclusion
This study underscores the importance of AQP4-specific Tfh and Th17 cells in NMOSD pathogenesis, highlighting CXCL9 as a potential therapeutic target for managing CNS inflammation.
